T&J brothers group Cofounder Xingyu Yang(James) bought large share in Marizyme, Inc.
“Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is now registered and licensed for import into India through Marizyme’s distribution partner Regency Lifesciences” From the online news. Xingyu Yang (James, the cofounder of T&J brothers group.LLC) put large shares in Marizyme, Inc. as they announce the transfer to the Nasdaq market soon. He thinks that a wise investment for the company and could help the science world become better.
About Marizyme, Inc.
Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The company’s flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the E.U. and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase® platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.
About Xingyu Yang(James)
Xingyu Yang (James) established and operated private equity fund T&J Brothers group, LLC in Los Angeles. He specializes in private equity fund investment and public transactions, financial advisory, planning, and strategic asset allocation. He was involved in the merger of IMMUNE Bio (biotech) IPO and Armo M&A. He is a follower of value investing. He is focus on future growth and enhancement of private equity in the industry.He is currently one of the youngest fund managers in Los Angeles.
He is currently graduating from U.C. Riverside and Participating in the school UCR investment club investment community and in the East Los Angeles College founded the investment analysis community.
Before the interview with Howard Marks (Oak Investment Company CEO), he established his own investment beliefs, long-term value investment. James also a SkyBridge Alternative (salt) young leader. A member of the California alternative investment association. One of the young members of the California Association of municipal finance officials. Previously, he was a speaker at the Opal group’s financial summit. He focuses on the concept of value investment and analysis. In the private equity fund T & J Brothers group, LLC will publish views on investment and analysis every time. He has five years of investment and analysis experience in U.S. stocks and has published an analysis of individual companies with James Early (motley fool manager).